Soliris (Alexion Pharma) rejected by UK Health Ministers for Haemolytic Uraemic Syndrome

Soliris (eculizumab)from Alexion Pharma was referred in the UK to the Advisory Group for National Specialised Services (AGNSS) instead of NICE and AGNSS recommended the $400 000 per patient, per year, drug for treatment of patients with atypical Haemolytic Uraemic Syndrome (aHUS), a rare, chronic blood disease. The decision of AGNSS was overruled by Health Ministers and the application has now been referred to NICE.